Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Paolo Sportoletti, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser, Jeff P. Sharman

Blood (2024) 144 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2024-198372

Published: 2024

Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2024-199276

Published: 2024

Journal Articles

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Jeff P. Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2024-200632

Published: 2024

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Karyotype and outcome in CLL

Stephen P. Mulligan

Blood (2023) 142 (5): 402–404.

https://doi.org/10.1182/blood.2023020769

Published: 2023

Journal Articles

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion

Yandong Shen, Jane A. Freeman, Juliette Holland, Kartik Naidu, Ann Solterbeck, Nenna Van Bilsen, Paul Downe, Ian Kerridge, Lucinda Wallman, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Gabriela Martins Costa Gomes, Chloe M. Doyle, Kerrie J. Sandgren, Stuart Turville, Anthony L. Cunningham, Stephen P. Mulligan

Blood (2022) 140 (25): 2709–2721.

https://doi.org/10.1182/blood.2022017814

Published: 2022

Includes: Supplemental data

Journal Articles

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

Narjis Fatima, BSMedTech,MPhil, Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Edwin Iwanowicz, PhD, Richard Christopherson, PhDEmeritus Professor, Giles Best, BSc, PhD, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2019) 134 (Supplement_1): 1735.

https://doi.org/10.1182/blood-2019-132160

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Blood (2019) 133 (19): 2031–2042.

https://doi.org/10.1182/blood-2018-08-870238

Published: 2019

Includes: Supplemental data

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Narjis Rizwan, BSMedTech, MPhil, PhD, Yandong Shen, BMedSc (Hon), Edwin Iwanowicz, PhD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Kyle R Crassini, MBBS, BSc, Richard Christopherson, PhD Emeritus Professor, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 3145.

https://doi.org/10.1182/blood-2018-99-115555

Published: 2018

Journal Articles

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Isabelle G. Solman, MS, Marlene Taylor, MS, Hana You, MS, Susan M. O'Brien, MD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, John C. Byrd, MD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Ann Mongan, PhD

Blood (2018) 132 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2018-99-110848

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor

Blood (2018) 132 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2018-99-118264

Published: 2018

Journal Articles

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Blood (2017) 129 (19): 2612–2615.

https://doi.org/10.1182/blood-2016-12-737346

Published: 2017

Includes: Supplemental data

Journal Articles

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

Blood (2015) 126 (23): 4146.

https://doi.org/10.1182/blood.V126.23.4146.4146

Published: 2015

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

NARROW

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Karyotype and outcome in CLL

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion

TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only